Clinical Trials Browser

INDUSTRY × Interventional × poly ICLC × Clear all

NCT02078648 2025-02-03

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Phase 1/2 Completed

74 enrolled 19 charts

Glioblastoma

NCT06614140 2024-09-26

Personalized Neoantigen Cancer Vaccine for Patients with Solid Tumors

Phase 1/2 Active not recruiting

Neoplasms

NCT02873819 2022-03-08

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT03380871 2021-02-26

A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02897765 2021-02-25

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Phase 1 Completed

DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Skin Neoplasms

NCT03162562 2020-12-22

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

Phase 1 Terminated

Ovarian Neoplasms

NCT02423863 2020-12-17

Poly-ICLC

Phase 2 Completed

DermatologicHead & NeckSarcoma

Head and Neck Neoplasms, Melanoma, Neoplasms, Sarcoma

NCT03597282 2020-09-03

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

Phase 1 Terminated

Melanoma

NCT02947854 2019-08-28

Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant

Phase 1 Completed

Healthy Volunteer

NCT02149225 2018-08-07

GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients

Phase 1 Completed

Glioblastoma

NCT02413827 2017-04-07

A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

Phase 1/2 Terminated

Melanoma

NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Phase 1/2 Completed

BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

NCT00493545 2008-05-07

Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia

Phase 1 Unknown

Uterine Cervical Dysplasia